Table 1 Selected co-receptor drug discovery & development deals
From: Industry pursues co-stimulatory receptor immunomodulators to treat cancer
Company | Partner | Targets | Potential value | Date |
|---|---|---|---|---|
BMS | Medarex | CTLA-4, PD-1 | $2.4 billiona | 7/28/2009 |
GlaxoSmithKline (GSK) | University of Texas MD Anderson Cancer Center | OX40 | $335 million | 12/7/2012 |
GSK | Amplimmune | PD-1 | $508 million | 8/4/2010 |
MedImmune | Cancer Research Institute; Ludwig Institute for Cancer Research | CTLA-4 OX40 PDL1 (programmed cell death ligand 1) | n/a | 10/9/2012 |
MedImmune | AgonOx; Providence Cancer Center | OX40 | n/a | 10/31/2011 |
4-Antibody, Recepta BioPharma | Ludwig Institute for Cancer Research | n/a | n/a | 1/29/2013 |
